Literature DB >> 11069237

Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects.

D V Havlir1, R D Schrier, F J Torriani, K Chervenak, J Y Hwang, W H Boom.   

Abstract

To characterize the influence of highly active antiretroviral therapy (HAART) on cell-mediated immunity (CMI) to Mycobacterium avium complex (MAC), we measured immune responses to M. avium in human immunodeficiency virus (HIV)-infected individuals before and during HAART, in subjects with a history of disseminated MAC (DMAC), and in HIV-uninfected control subjects. Forty-seven percent of untreated HIV-infected patients and 78% of control subjects exhibited in vitro proliferative responses to M. avium (P=.03). Proliferative responses to M. avium increased after HAART for 3 months and were present in 77% of subjects after 6 months. Mean interferon-gamma production increased from 199 to 1156 pg/mL after HAART (P=.06). Proliferative responses to M. avium occurred in 76% of DMAC subjects receiving HAART. CD4 and CD8 but not gammadelta T cells expanded in response to M. avium. CMI to M. avium reconstitutes rapidly after HAART and appears sustained even with partial viral suppression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069237     DOI: 10.1086/317620

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.

Authors:  Estibaliz Lazaro; Gaelle Coureau; Jérémie Guedj; Patrick Blanco; Isabelle Pellegrin; Daniel Commenges; François Dabis; Jean-François Moreau; Jean-Luc Pellegrin; Rodolphe Thiébaut
Journal:  Antivir Ther       Date:  2006

Review 2.  Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Christophe Piketty; Michel D Kazatchkine
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

3.  Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.

Authors:  Y Shen; L Shen; P Sehgal; D Zhou; M Simon; M Miller; E A Enimi; B Henckler; L Chalifoux; N Sehgal; M Gastron; N L Letvin; Z W Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Authors:  Adriana Weinberg; Ruth Dickover; Paula Britto; Chengcheng Hu; Julie Patterson-Bartlett; Joyce Kraimer; Howard Gutzman; William T Shearer; Mobeen Rathore; Ross McKinney
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

5.  Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Authors:  Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

6.  Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Gregory B Pott
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 7.  Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?

Authors:  Christoph G Lange; Ian J Woolley; Reinhard H Brodt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.

Authors:  S D Lawn; R J Wilkinson
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

9.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.